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In patients with proven esophageal hemorrhage, is esophageal ligation still
treatment of choice in secondary prophylaxis of variceal bleeding? A
comparative literature review
Abstract
Background: Esophageal bleeding has an estimated mortality rate of at least 25% with the index bleed, an
estimated 35% to 42% risk of death within the first six weeks, and up to 75% chance of a rebleed at one year.
Prevention of chronic variceal rebleeding is critical and most crucial in the first three months following the
index bleed. To address this, several medical and surgical therapies have been studied and used with various
levels of success. For several years, esophageal variceal ligation (EVL) has been accepted as the best overall
prevention for chronic variceal rebleeding, given the advantages and disadvantages of each treatment method.
However, recent trials in pharmacological therapy using beta-blockers, in combination with a nitrate, have
shown greater efficacy in preventing recurrent variceal bleeding, studies combining pharmacological and
nonpharmacological modalities have been performed, and technological advances have decreased the
rebleeding rate after transesophageal intrahepatic portosystemic shunt (TIPS) therapy. This has created the
possibility that another treatment may be better than EVL alone. Further study and trials are necessary to
determine if esophageal variceal ligation is still the treatment of choice for secondary prevention of variceal
rebleeding.
Clinical Question: In patients with proven esophageal hemorrhage, is esophageal ligation still the treatment of
choice in secondary prophylaxis of variceal bleeding?
Study Design: Exhaustive search of available medical literature employing CINAHL, MEDLINE, Evidence
Based Medicine Reviews Multifile, BIOSIS preview databases. Studies were found in key industry journals,
and article reference lists were combed for additional trials meeting inclusion criteria.
Methods: Independent review of data and methodology of published randomized control trials addressing
long-term prevention of esophageal variceal bleeding using esophageal variceal ligation as compared to
another treatment modality, or as compared to EVL plus another therapy, performed within the last 10 years,
and free on internet search.
Results: In reviewing the efficacy of esophageal variceal ligation (EVL) therapy to other modes of treatment
for secondary prophylaxis of variceal bleeds, one study showed an improved benefit in variceal rebleeding rate
and overall bleeding rate when esophageal variceal ligation was compared to propranolol, a nonselective beta-
blocker, plus isosorbide mononitrate (ISMN). In two studies comparing EVL to ISMN plus nadolol, a
different nonselective beta-blocker, one study reported no significant difference in rebleeding, overall bleed, or
mortality rates and the other trial concluded that EVL was less effective than nadolol plus ISMN and EVL, in
isolation, had an associated higher rate of major complications. A fourth trial compared variceal ligation to a
combination therapy of EVL plus nadolol and found that nadolol plus EVL reduced the incidence of variceal
rebleeding as compared to EVL, but did not reduce the risk of mortality. When evaluated against
transesophageal intrahepatic portosystemic shunt (TIPS), EVL proved to be less effective than TIPS, nor did
it improve the two-year survival rate or encephalopathy rate. In the final study reviewed, a combination
therapy of variceal ligation plus propranolol was found to be nearly as effective as TIPS, and with an equally
effective survival rate, but ligation plus propranolol had approximately half the risk of encephalopathy. These
randomized controlled trial results showed contradictory evidence for the efficacy of esophageal variceal
ligation in the control of secondary variceal rebleeding. Esophageal variceal ligation therapy, alone, did not
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show a clear benefit in the long-term prevention of variceal rebleeding as compared to beta-blocker plus
nitrate, EVL plus beta-blocker, or TIPS. However, when EVL was paired with a beta-blocker, and pitted
against variceal ligation alone, the combination comparatively reduced the incidence of variceal rebleeding.
Conclusion: Esophageal variceal ligation, in isolation, shows no superiority to treatment with beta-blocker
and nitrate, or TIPS procedure, and is less effective than EVL plus nadolol in the prevention of secondary
variceal bleeding.
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Abstract   
 
Objective:  To review the efficacy of current treatment modalities in comparison 
to esophageal variceal ligation therapy for the long-term prevention of esophageal 
variceal rebleeding. 
Background:  Esophageal bleeding has an estimated mortality rate of at least 
25% with the index bleed, an estimated 35% to 42% risk of death within the first six 
weeks, and up to 75% chance of a rebleed at one year.  Prevention of chronic variceal 
rebleeding is critical and most crucial in the first three months following the index bleed.  
To address this, several medical and surgical therapies have been studied and used with 
various levels of success.  For several years, esophageal variceal ligation (EVL) has been 
accepted as the best overall prevention for chronic variceal rebleeding, given the 
advantages and disadvantages of each treatment method.  However, recent trials in 
pharmacological therapy using beta-blockers, in combination with a nitrate, have shown 
greater efficacy in preventing recurrent variceal bleeding, studies combining 
pharmacological and nonpharmacological modalities have been performed, and 
technological advances have decreased the rebleeding rate after transesophageal 
intrahepatic portosystemic shunt (TIPS) therapy.  This has created the possibility that 
another treatment may be better than EVL alone.  Further study and trials are necessary to 
determine if esophageal variceal ligation is still the treatment of choice for secondary 
prevention of variceal rebleeding.  
 
Clinical Question:  In patients with proven esophageal hemorrhage, is 
esophageal ligation still the treatment of choice in secondary prophylaxis of variceal 
bleeding? 
 
Study Design:  Exhaustive search of available medical literature employing 
CINAHL, MEDLINE, Evidence Based Medicine Reviews Multifile, BIOSIS preview 
databases.  Studies were found in key industry journals, and article reference lists were 
combed for additional trials meeting inclusion criteria.  
Methods:  Independent review of data and methodology of published randomized 
control trials addressing long-term prevention of esophageal variceal bleeding using 
esophageal variceal ligation as compared to another treatment modality, or as compared 
to EVL plus another therapy, performed within the last 10 years, and free on internet 
search. 
Results:  In reviewing the efficacy of esophageal variceal ligation (EVL) therapy 
to other modes of treatment for secondary prophylaxis of variceal bleeds, one study 
showed an improved benefit in variceal rebleeding rate and overall bleeding rate when 
esophageal variceal ligation was compared to propranolol, a nonselective beta-blocker, 
plus isosorbide mononitrate (ISMN).  In two studies comparing EVL to ISMN plus 
nadolol, a different nonselective beta-blocker, one study reported no significant 
difference in rebleeding, overall bleed, or mortality rates and the other trial concluded 
that EVL was less effective than nadolol plus ISMN and EVL, in isolation, had an 
associated higher rate of major complications.  A fourth trial compared variceal ligation 
to a combination therapy of EVL plus nadolol and found that nadolol plus EVL reduced 
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the incidence of variceal rebleeding as compared to EVL, but did not reduce the risk of 
mortality.  When evaluated against transesophageal intrahepatic portosystemic shunt 
(TIPS), EVL proved to be less effective than TIPS, nor did it improve the two-year 
survival rate or encephalopathy rate.  In the final study reviewed, a combination therapy 
of variceal ligation plus propranolol was found to be nearly as effective as TIPS, and with 
an equally effective survival rate, but ligation plus propranolol had approximately half 
the risk of encephalopathy. 
These randomized controlled trial results showed contradictory evidence for the 
efficacy of esophageal variceal ligation in the control of secondary variceal rebleeding.  
Esophageal variceal ligation therapy, alone, did not show a clear benefit in the long-term 
prevention of variceal rebleeding as compared to beta-blocker plus nitrate, EVL plus 
beta-blocker, or TIPS.  However, when EVL was paired with a beta-blocker, and pitted 
against variceal ligation alone, the combination comparatively reduced the incidence of 
variceal rebleeding. 
Conclusion:  Esophageal variceal ligation, in isolation, shows no superiority to 
treatment with beta-blocker and nitrate, or TIPS procedure, and is less effective than EVL 
plus nadolol in the prevention of secondary variceal bleeding. 
Keywords:  beta-blockers, cirrhotic, EIS, esophageal injection sclerotherapy, 
esophageal variceal ligation, esophageal varices, EVL, gastrointestinal, octreotide, 
omeprazole, portal hypertension, prevention, propranolol, prospective, randomized, TIPS, 
transjugular intrahepatic portosystemic stent, trial, variceal bleeding, varix, vasopressin. 
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INTRODUCTION AND BACKGROUND 
Many factors may lead to the development of portal hypertension, which is 
defined by pathological increase in the pressure in the portal venous system.1  In turn, 
portal hypertension may be the result of chronic liver injury, and can be cirrhotic or 
noncirrhotic, in nature.   
The main causes of cirrhotic liver disease with elevated portal hypertension are 
alcoholic cirrhosis, chronic Hepatitis B or Hepatitis C virus, primary biliary cirrhosis, 
hemochromatosis or Wilson’s disease.  Cirrhotic liver disease is a late stage development 
in which there is liver architecture degeneration concomitant with progressive hepatic 
fibrosis, followed by formation of dysfunctional nodules.  As a result of these changes, 
there occurs the synchronous development of portal hypertension.  The continuum of 
cirrhosis ranges from potential reversibility in its early stages, to ultimately irreversible 
advanced cirrhosis which has few options for treatment other than hepatic lobectomy or 
full liver transplant.  While in that continuum, one possible life-threatening complication 
is esophageal variceal hemorrhage, a sign of decompensated liver disease.  (Other 
complications may include ascites, spontaneous bacterial peritonitis, hepatorenal 
syndrome, hepatic encephalopathy, hepatopulmonary syndrome, and hepatocellular 
carcinoma).2   
The importance of esophageal variceal bleeding, as a major complication of portal 
hypertension resulting from liver cirrhosis3, cannot be overstated as it is the leading cause 
of cirrhosis-related death.4  Without intervention following a variceal hemorrhage event, 
approximately 50% of patients will die within three months and mortality is as high as 
66% at one year.5  Even with intervention, 25% of cirrhotic patients presenting with a 
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major index variceal bleed will die as a result, and for the balance of patients that survive 
it, there is a 70% chance of rebleeding with a similar mortality.4  Abid et al state that 
gastroesophageal varices have been identified in approximately 30% of patients with 
compensated cirrhosis6, and the prevalence of esophageal varices that have been 
identified in patients with liver cirrhosis may range from 60% to 80%.7  Other research 
cites esophagogastric varices as responsible for 60%-80% of first bleeds in 
decompensated cirrhotic patients with portal hypertension.8  Thus, immediate delivery of 
efficacious treatment is of vital importance and prevention of rebleed is a major concern.   
Noncirrhotic liver disease also may result in acute or chronic variceal bleeding 
leading to a high morbidity and mortality.  Noncirrhotic liver disease with portal 
hypertension is known by different names around the world.  It is called noncirrhotic 
portal fibrosis (NCPF) in India, and it is known as idiopathic portal hypertension (IPH) in 
Japan, and seen in this literature search as noncirrhotic portal hypertension (NCPH).  We 
now know that noncirrhotic elevation of portal hypertension is commonly caused by 
idiopathic portal hypertension (IPH), which exists more in developing countries, and 
schistosomiasis, which is one of the most common causes of noncirrhotic portal 
hypertension worldwide1.  Although the exact mechanisms are, as yet, unknown, factors 
believed to play a role in the development of idiopathic portal hypertension are recurrent 
infections, altered immune response, genetic predisposition, hypercoagulability, HIV 
infection, all leading to increased resistance to portal flow.  Liver function is preserved 
more in NCPH/IPH, as opposed to alcoholic cirrhosis.  Thus, while variceal bleeding 
occurs with IPH, and is the most common clinical presentation of IPH1, it is generally 
better tolerated than in cirrhotic liver disease.  Patients with IPH may remain 
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asymptomatic during the early stages of the disease, but histological changes can develop 
later, engendering symptoms of variceal bleeding, and requiring a subsequent liver 
transplant.  The only form of treatment that cures both the underlying liver disease and 
the portal hypertension is liver transplantation.9  All patients with esophageal varices 
should be evaluated for liver transplantation, however, only a small percentage of the 
patients live long enough to benefit from this intervention.  Thus, whether the diseased 
state is noncirrhotic or cirrhotic in etiology, there exists the imperative to find the most 
effective treatment for prevention of secondary variceal bleeding to reduce the life-
threatening hemorrhage that may ensue from cirrhotic or noncirrhotic liver disease. 
Long-term therapeutic modalities for prevention of esophageal variceal rebleeding 
are needed after initially gaining control of the index variceal bleed.  These treatments 
may be noninvasive or invasive in nature, or a combination of the two.  Recent studies 
using medical intervention for the prevention of recurrent bleed have included vasoactive 
drugs, such as nonselective beta blockers, nitrates, and somatostatin analogues.  Other 
nonpharmacological modalities seen commonly in trials for prevention of secondary 
variceal bleeding include esophageal injection sclerotherapy (EIS), esophageal variceal 
ligation (EVL), also known as esophageal band ligation (EBL), and transesophageal 
intrahepatic portosystemic stent (TIPS). 
Pharmacological intervention, for the prevention of recurrent variceal bleeding, 
addresses the development of increased portal pressure, which may lead to the increased 
likelihood of variceal hemorrhage.9  The goal of long-term pharmacological therapy then, 
is to decrease the baseline hepatic venous portal pressure and, thereby, decrease the 
incidence of variceal bleeding.  Nonselective beta blockers can address this problem, but 
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two issues are persistent: the high rate of nonresponders, regardless of the dose delivered, 
and the unreliable and variable reduction of portal pressure seen in those who do respond 
to beta-blockers.10  By the early 1990s, meta-analysis indicated that beta-blockers were 
more successful at preventing primary hemorrhage than in preventing recurrent 
hemorrhage after the index bleed.9  More recent studies showed that beta-blockers 
decreased variceal rebleeding by 40% and improved overall survival by 20%, but a high 
nonresponder rate and contraindications presented problems for its use.11   
Occurring simultaneously with increased portal hypertension is an increase in 
portal blood flow, caused by arteriolar splanchnic vasodilatation and hyperkinetic 
circulation11.  One vasodilator, 5-isosorbide mononitrate (ISMN), has been used 
extensively in studies, and has been shown to reduce portal pressure through a decrease 
in portal blood flow and a decrease in the intrahepatic resistance.11  Rodríguez-Vilarrupla 
et al (2007) support this theory, hypothesizing that nitrates probably relax smooth muscle 
and myofibroblasts.12  Subsequently, trials using beta blockade augmented with ISMN 
have been performed and appear to have increased effectiveness when used as secondary 
prophylaxis for variceal bleeding.  Other drugs, such as octreotide, a somatostatin 
analogue with known inhibitory action on vasodilatory peptide release, also help to 
mitigate the hyperemic portal response to a recent meal by reducing postprandial 
hyperemia, thus decreasing the risk of a recurrent variceal bleed.13  No study comparing 
variceal ligation with octreotide for prevention of variceal rebleeding was found during 
this literature search. 
Endoscopy, a nonpharmaceutical tool, does not affect the causes of portal 
hypertension.  Thus, both endoscopic injection sclerotherapy (EIS) and endoscopic 
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variceal ligation (EVL) have short-term effectiveness, with frequent variceal recurrence 
and rebleeding.  EIS controls initial bleeding and prevents further hemorrhage by 
thrombosing esophageal vessels or thickening the esophageal mucosa over the varix.  A 
sclerosant is injected either directly into the vein (intravariceal) or next to it in the 
mucosa (paravariceal), or a combination of the two methods.  Many variables exist 
between providers, including type, concentration, and volume of sclerosant, tools used, 
and technique, thus, EIS results remain somewhat provider-dependent, which may lead to 
variability in study outcome.4, 13 Although esophageal injection sclerotherapy is widely 
used to control variceal bleeding and to eradicate varices to prevent rebleeding, EIS is 
associated with a rebleeding rate as high as 50% and complications of fever, esophageal 
ulceration or stricture may occur in up to 40% of patients, and with a mortality rate of one 
to two percent.14  
Endoscopic variceal ligation (EVL), an alternative to EIS, is an attractive tool 
because it results in less variceal rebleeding, and in fewer complications and deaths than 
injection sclerotherapy.4  EVL uses small elastic ‘O’ bands which, when loaded onto the 
end of the endoscope, may be used to encircle and tie off the varix, leading to tissue 
necrosis and sloughing.  EVL does not use a needle or sclerosant, making it a less 
invasive therapy than injection sclerotherapy.  However, the single band ligators need to 
be reloaded, taking up precious time during an active bleed, and repeated removal and 
reinsertion of the tube increases the chance of mucosal tears or hemorrhage, esophageal 
perforation, and discomfort for the patient. Multiple-band ligators have a suction cup on 
the end of the endoscope decreasing the visual field by 30%4 and which may clot with 
blood during an active bleed, decreasing visibility even more.  Total variceal eradication 
 13 
is achieved more quickly with banding than with EIS15 and EVL-caused esophageal 
ulcers are more superficial and resolve more rapidly than EIS-induced ulcers.4  
Bacteremia, appears to occur less often and has a lower rate of associated spontaneous 
bacterial peritonitis or pneumonia with band ligation treatment as compared to injection 
sclerotherapy.4 
Transjugular intrahepatic portosystemic stent (TIPS) shunt is generally used as an 
emergency treatment for patients who fail endoscopic treatment.  The hepatic vein is 
cannulated via the jugular vein and a tract is opened in the liver tissue to the portal vein, 
thus decompressing the portal system, thereby, lowering variceal pressure, and hopefully, 
decreasing the rate of variceal hemorrhage.  The procedure does benefit patients with low 
rebleeding rates, but studies show that rebleeding is common secondary to stent 
occlusion, and TIPS is associated with an increased risk of encephalopathy.16 
Invasive portocaval shunt surgery may decrease variceal rebleeding rates but has 
an associated higher risk of encephalopathy and a greater risk of mortality.  No studies 
were found comparing variceal ligation to portocaval shunt surgery for this review. 
 
METHODS 
An electronic search for relevant articles was conducted of available medical 
literature employing CINAHL, MEDLINE, Evidence Based Medicine Reviews Multifile, 
BIOSIS preview databases.  Search terms in the database review included beta-blockers, 
bleed, cirrhotic, esophageal injection sclerotherapy, esophageal variceal ligation, 
esophageal varices, gastrointestinal, octreotide, prevention, propranolol, prospective, 
randomized, TIPS, transjugular intrahepatic portosystemic stent, trial, varix.  Studies 
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were found in key industry journals, among them Hepatology, Gastroenterology, Gut, 
Journal of Gastroenterology and Hepatology, Digestive Diseases and Sciences, Annals of 
Surgery, NEJM, Am J of Gastroenterology, and Endoscopy.  Relevant review articles and 
the bibliographic reference lists were examined for additional sources.  Search of the 
above sources was limited to articles of published studies available on the internet, and 
available without fee. 
Criteria for inclusion were randomized control trials (RCT) or prospective study 
status performed on cirrhotic and noncirrhotic patients with evidence of esophageal 
varices.  Studies had to address variceal rebleeding rate after therapy as a primary or 
secondary endpoint.  Publication was required within the last 10 years (2000 to 2009) and 
the studies needed to be available in the English language.  
Excluded were patient populations without any history of upper gastrointestinal 
bleeding or those with a bleeding history other than the index GI bleed, those patients 
with varices which were deemed “likely to bleed” but had no evidence of prior bleed, and 
those patients without gastroesophageal varices.  Any study published before the year 
2000 was excluded from this systematic review. 
An independent evaluation was performed by a single individual analyzing data 
and methodology from the above published randomized control trials or prospective 
studies which met the inclusion criteria. 
 
RESULTS 
This review evaluated six studies regarding the efficacy of esophageal variceal 
ligation (EVL) therapy in control of variceal rebleeding as compared to other treatment 
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modalities (see Table I).  Three of these studies tested esophageal ligation against a 
combination pharmacological treatment of beta-blocker plus isosorbide mononitrate, with 
mixed results, while a fourth study compared EVL to ligation augmented by a beta-
blocker and found that ligation alone was not as effective at reducing secondary 
esophageal bleeding as ligation plus a beta-blocker.  The remaining two studies compared 
EVL, or EVL plus beta-blocker, against transesophageal intrahepatic portosystemic stent 
therapy.  These last two trials found TIPS to be more effective than EVL, but with no 
increase in mortality rate in the first study, and a recommendation that EVL plus 
propranolol be used as initial treatment for the prevention of variceal rebleeding in the 
second.  All included studies were randomized and earned a Jadad validity score of three 
out of five points. 
The first three studies reviewed addressed the use of endoscopic variceal ligation 
versus a pharmacological agent.  In a prospective randomized controlled study, Sarin et 
al., 2005, used propranolol plus isosorbide mononitrate (ISMN) as a comparison.  A 
group of 137 patients with proven esophageal varices as the bleeding source on upper 
gastrointestinal endoscopy were randomized to receive treatment by endoscopic variceal 
ligation every 2 weeks until variceal obliteration or until the varix was too small that to 
be banded.  The therapy arm treatment consisted of oral propranolol twice daily, titrated 
upwards until a 25% decrease in heart rate or 55 bpm, or 240mg/day was reached.  After 
the propranolol dose was stabilized, twice daily oral ISMN was added. Again, the 
medication dose was titrated upwards until a total dose of ISMN 40mg/day was reached 
or until side effects precluded further dose elevations.  This study, which had a mean 
follow up of 11.8 months (range 1-40 months), targeted esophageal variceal bleeding as 
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its primary endpoint.  The overall bleeding rate for the EVL arm was reported as 14.1% 
while the drug treatment arm showed a 27.2% bleed rate (P=0.06) during the study 
period.  When esophageal variceal rebleeding alone was tallied, 5/71 EVL patients (7%) 
rebled, versus 15/66 patients (22.7%) in the drug therapy arm.  “The actuarial probability 
of bleed at the end of 24 and 36 months was 42% and 66%, respectively, in the drug 
therapy arm, compared to 33% and 47% in the EVL arm (P= 0.10, log rank test)”.17  
When etiology was examined as a possible confounder of variceal bleeding, analysis 
revealed a cirrhotic bleeding rate of 12.7% and 23.5% in the EVL and drug treatment 
arms, respectively.  However, when the noncirrhotic bleeding rate was calculated, only 
4.7% of the patients bled in the EVL arm and a much higher 40% bled in the drug 
therapy arm of the trial.  Bleeding rates calculated according to Child’s classification 
status are also included in this study.  (Child’s classification, sometimes referred to as 
Child-Pugh classification, uses serum albumin concentration, bilirubin level, prothrombin 
time, and the presence of ascites and encephalopathy to measure liver dysfunction level.  
Child A classification is well compensated liver disease, B class is functionally 
compromised, and C class is decompensated disease and, thus more likely to have 
associated variceal bleeding.21)  In summary, esophageal variceal ligation proved more 
effective than pharmacological therapy in patients with noncirrhotic portal hypertention 
(NCPH) but both were equally effective in cirrhotic patients. 
Romero et al15 conducted a randomized controlled trial, published in 2006, using 
nadolol with ISMN in comparison to EVL.  This study followed 109 cirrhotic patients 
with a recent variceal bleed for a mean follow up period of 17 and 19 months in the 
nadolol/ISMN and EVL groups, respectively.  Fifty-seven patients had 40mg of once 
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daily oral nadolol titrated upwards until a 25% reduction in heart rate or until a heart rate 
of 55 bpm was reached.  Once this dose was stabilized, twice daily 10mg ISMN was 
added and titrated up to 40mg/day or until side effects compromised further dosage 
increase.  Treatment failure occurred when patients suffering from side effects to beta-
blockers required complete treatment withdrawal.  In the esophageal variceal ligation 
group, ligation banding was performed at 2 week intervals until variceal eradication.  
Originally, the study design dictated use of a single band ligation device, requiring use of 
an overtube, but later in the study a multibanding ligation device was used for treatment.  
When a multiband ligator device was used, no more than 10 bands were placed per 
session.  The two-week EVL interval schedule was changed only if large ulcers or 
esophageal stenosis was found.  Once ligation was complete, one or two sclerotherapy 
session were given to residual varices.  In the pharmacological group, patients were 
followed every 3 months.  The EVL arm patients had endoscopy at one, three, and six 
month intervals and every six months thereafter.  GI and variceal rebleeding events were 
the primary endpoints.  Romero et al.15 observed no significant difference in esophageal 
variceal rebleeding rate between nadolol plus ISMN (21/57 patients or 36.8%) and EVL 
groups (17/52 patients or 32.7%), respectively.  Secondary endpoints included survival 
time and complications.  Mortality rate was rated as similar between both groups, i.e., 
19.3% versus 19.2% (P=0.9) in the nadolol/ISMN and the EVL groups, respectively.  
Likewise, other complications were reported as not significantly different between the 
two groups.15 
A third study, variceal ligation therapy with a pharmaceutical challenge, was 
performed by Villanueva et al.18  Primary endpoints of recurrent bleeding, complications, 
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and death were studied by recruiting 144 adults, aged 18 and up, with cirrhosis and 
esophageal variceal hemorrhage.  Seventy-two patients were randomly assigned to each 
group.  In one treatment arm, nadolol was initiated at a once daily dose of 80mg, and then 
adjusted over the following five days to decrease the baseline heart rate by 25%, but not 
below 55 bpm.  After heart rate reduction and stabilization, isosorbide mononitrate 
(ISMN) was begun with a 20mg bedtime dose and, subsequently, increased to 40mg 
twice daily, or until side effects prevented further dosage increase.  The other 72 
treatment arm subjects received esophageal ligation using either a single band and an 
overtube device or using a multiband ligating device.  A maximum of eight bands per 
session were placed at randomization date, on day seven, and each two to three weeks 
until eradication, or until each varix was too small to be banded.  Endoscopy follow up 
was performed three months following randomization and at six month intervals 
thereafter.  This RCT calculated a 49% rebleed rate for the EVL only group as compared 
to a 33% rebleed rate for the nadolol/ISMN treatment arm over a median follow up 
period of 21 months.  Actuarial probability of survival was similar in the two groups at 
two years (P=0.52).  Treatment complications, classified as severe occurred in 12% of the 
ligation arm, but in only 3% of the pharmaceutical arm (P=0.05).  However, when the 
overall complication rate was assessed, the EVL group had a 31% complication rate as 
opposed to a 26% rate in the medication group (P=0.71).18 
This literature search found one study, by de la Peña et al19, which compared 
variceal ligation plus nadolol to EVL alone for variceal rebleeding prophylaxis.  De la 
Peña et al.19 enlisted 80 cirrhotic adults, aged 18-75 years, with esophageal or 
gastroesophageal varices for this randomized study conducted at four separate hospital 
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sites.  Initially, all patients received emergency endoscopy EVL or endoscopic injection 
sclerotherapy (EIS) plus somatostatin at 250 micrograms/hour for five days.  The variceal 
ligation arm patients were treated with multiband devices (the Six Shooter-Saeed Multi-
Band Ligator and the speed band by a different maker).  Ligation was started at the cardia 
or just inferior to it and repeated at 10 to12 day intervals until eradication. The EVL plus 
nadolol arm patients received a once daily oral nadolol dose, starting at 40mg daily, 
which was increased in dosage until a 25% decrease in resting heart rate was reached.  
Follow up was performed in both groups at 3-, 6-, and 12-month intervals, and then 
annually thereafter.  Actual mean follow up was 15 +/- 8 months in the EVL group, and 
17.5 +/- 7.8 months in the EVL plus nadolol group.  The primary endpoint was variceal 
rebleeding.  Several secondary endpoints were sought, among them, mortality rate, 
variceal eradication, recurrence rate of esophageal varices, complications of treatment in 
either protocol arm, or treatment failure.  The rebleeding rate reported for those patients 
treated with the combination of EVL plus nadolol was 14% (6/43 pts), for ligation alone, 
38% (14/37 pts).  Mortality was similar in both groups, as was the median number of 
endoscopy treatments needed to achieve variceal eradication (three; range one to seven).  
The benefit of nadolol adjuvant to EVL therapy was observed when the probability of 
variceal recurrence was calculated for the first year following treatment.  Varices 
reappeared after eradication in 54% of the EVL plus nadolol group, as compared to a 
77% recurrence rate in the EVL alone treatment group (P=0.06, log rank test).  
Additionally, researchers saw a trend towards fewer EVL sessions to treat new varices in 
the combined therapy group.19 
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Two studies using transesophageal intrahepatic portosystemic shunt (TIPS) were 
reviewed.  The first, a randomized control trial by Pomier-Layrargues et al5, published in 
2001, compared the variceal rebleeding and two year survival rates in moderate to severe 
cirrhotic patients treated with esophageal variceal ligation (EVL) as opposed to TIPS.  
The variceal rebleeding rate at two years with TIPS was 18.5% versus 66% with EVL 
(p<0.001) for 80 patients, aged 18-75 years, with cirrhosis and an episode of variceal 
hemorrhage. Nine variceal rebleeding events occurred in 8/41 (19.5%) patients in the 
TIPS arm due to stent stenosis and stent thrombosis.  Variceal bleeding occurred 30 times 
in 22/39 patients in the EVL group (56.4%).  Uncontrolled rebleeding occurred in 11 
patients in the ligation group (eight were rescued by emergency TIPS) but there was no 
evidence of uncontrolled rebleeding in the TIPS group.  Study authors concluded that 
TIPS significantly reduced the incidence of variceal rebleeding but did not increase the 
survival rate at two years when compared to variceal band ligation.  Since TIPS 
intervention is associated with an elevated incidence of hepatic encephalopathy, notation 
was made in this study that seven patients in each arm of the study had encephalopathy 
on the day of randomization.  During the follow up period (mean 20.9 months) the 
cumulative probability of developing encephalopathy at two years from date of study 
inclusion was not significantly different between groups (47% TIPS vs. 44% EVL).5 
A separate TIPS-related study, this one by Sauer et al20, compared TIPS to EVL 
plus propranolol.  Eighty-five cirrhotic adults, aged 31-87, with a single episode of acute 
esophageal variceal bleeding were enrolled into this long-term randomized control study.  
Primary endpoints compared recurrence of variceal bleeding, and secondary endpoints 
were death from any cause and encephalopathy.  The mean study length was 4.1 years in 
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the TIPS group, and 3.6 years in the EVL arm.  All patients with initial active variceal 
bleeding were treated with injection sclerotherapy using 5% ethanolamine oleate and 
subsequently underwent either the TIPS or EVL treatment protocol within 48 hours.  
TIPS arm subjects had stents dilated to 8-12mm and the portal venous pressure gradient 
was titrated to between 10 to15mmHg until the disappearance of variceal or collateral 
vessel perfusion in the portogram occurred.  After stent placement, continuous IV heparin 
was given for three days along with mezlocillin and metronidazole broad-spectrum 
antibiotic prophylaxis.  The patients undergoing endoscopic ligation in this study had 
multiple-band ligation sessions every one to two weeks until variceal eradication or until 
the varices were reduced in size and too small to be treated by ligation.  EVL therapy was 
augmented with twice daily oral doses of propranolol, starting at 40mg/day, and 
increased by 40mg/day, until resting heart rate was reduced to 75% of baseline.  All study 
participants were followed up at three month intervals during the first year after 
enrollment, at six month intervals during the second year, and annually thereafter.20 
Sauer et al.20 were successful in all TIPS shunt placements and in complete 
variceal eradication for all 43 TIPS-arm patients.  Rebleeding of varices occurred in 7/43 
(16.3%) of the TIPS arm patients.  In the EVL+ propranolol group, after a mean of 3.6 
endoscopic ligation sessions, taking approximately two months to complete, varices were 
obliterated in 37/42 (88%) of the patients and rebleeding occurred in 10/42 (23.8%).  
Researchers did not find the difference in the probability of esophageal rebleeding to be 
statistically significant.  The cumulative death rate for the TIPS arm was 24.1% and in 
the EVL group it was 17.8%.  Both groups had higher rates of death in patients with more 
advanced liver disease, specifically, Child C patients.  During the study period, the 
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calculated probability of encephalopathy was 40.5% in the TIPS arm and 20.5% in the 
EVL arm (P<0.05), and the analysis by Cox regression proved the Child-Pugh class and 
treatment arm were independent predictors for encephalopathy.20  Researchers concluded 
that, due to the beneficial efficacy and lower costs of treatment, endoscopic ligation 
therapy plus propranolol has use as the initial treatment for the prevention of recurrent 
variceal bleeding, whereas TIPS treatment should be reserved for rescue therapy after 
endoscopic and pharmacological treatments have been tried. 
 
DISCUSSION 
Studies regarding esophageal variceal rebleeding rates are cumbersome to 
compare for many reasons.  First, ethical limitations must be first and foremost in the 
researchers’ minds as they design a study.  Every trial design, in the face of an acute, and 
potentially life threatening esophageal bleed, must deliver what we know to be leading-
edge quality patient care and must not compromise the extension or quality of life for the 
sake of scientific experimentation. 
Secondly, variceal rebleeding study comparison is made challenging by the 
variety and nuances of measured endpoints.  For instance, prevention of recurrent 
variceal bleeding (secondary)17, 20 was measured in several studies and prevention of 
primary variceal bleed was measured in others.3, 22  Variceal bleeding was both a primary 
and secondary endpoint, as was any rebleeding, defined commonly as any episode of (GI) 
hematemesis or melena (or both) occurring during follow-up, as well as any “significant 
bleeding”  which was defined differently by each study group.  The incidence of side 
effects or complications of therapy were detailed in some studies, but not all, and each 
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study picked those side effects or complications they felt were important to follow, again 
making it difficult to compare studies across the board.  
Thirdly, the variety of therapeutic modalities used as comparisons to variceal 
ligation, be it vasoactive medications, EIS, or TIPS, created seemingly endless 
opportunities for study.  The difficulty in creating gold-standard randomized and blinded 
studies lies in the sheer number of viable options available, as well as in the impossibility 
of blinding such disparate therapies.  Propranolol, nadolol, timolol, isosorbide 
mononitrate, octreotide, vasopressin, and omeprazole8, to name a few, have all been used, 
alone or in combination, as pharmacological interventions in the studies found in this 
literature search.  Additionally, pharmacological agents were used as adjuvants to both 
endoscopic band ligation6, and to injection sclerotherapy.3   
Control of variceal rebleeding was achieved using multiple methods introducing 
confounding factors into the studies, thus reducing the ability to assess intervention 
effectiveness.  For example, Sauer et al.20 tested the effectiveness of EVL plus 
propranolol against TIPS therapy; if active bleeding occurred after endoscopic validation 
of esophageal varices, the patient underwent a balloon tamponade procedure and/or 
intravenous octreotide for 48 hours.  Likewise, Sarin et al. (2005) controlled rebleeding in 
both the EVL and the drug therapy study arms with vasoactive drugs using either 
terlipressin or somatostatin.  A study by Villanueva et al. (2001) compared EVL to 
nadolol plus ISMN, and treated patients with rebleeding varices with somatostatin, 
emergency sclerotherapy, or both.  In all three studies, rebleeding patients received 
emergency intervention, however, it is not apparent which, or how many, treatments they 
received.  In the Romero et al. (2006) study, which compared beta-blocker plus ISMN 
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against EVL plus sclerotherapy, all rebleeding patients were treated with injection 
sclerotherapy, but in doing so added a confounding factor to the pharmacological 
treatment arm.  In contrast, the study conducted by Pomier-Layrargues et al. (2001) 
treated variceal rebleeding by shunt revision (dilatation and/or addition of new stents) in 
the TIPS group, and treated the ligation group with additional banding.  Likewise, de la 
Peña et al. (2005) addressed active rebleeding rescue using the same treatment method to 
which the patients had been randomized.  In reviewing these interventions, it is a 
reasonable assumption that the emergency treatments, if different than the treatment 
being analyzed, may skew study outcomes by masking true endpoint occurrences through 
the addition of new variables.  While controlling rebleeding episodes is paramount, 
additional methods of bleeding control compound the difficulties in assessing which 
modality is affecting the change. 
Trial design inconsistencies further complicated comparison of esophageal 
rebleeding studies.  Sauer et al. (2002) chose to prophylactically treat the TIPS arm 
subjects with both IV heparin and broad-spectrum antibiotic therapies (mezlocillin and 
metronidazole) after stent placement.  Patients receiving EVL plus propranolol therapy 
did not receive anticoagulant or antibiotic prophylaxis.  Anticoagulant therapy can 
provoke rebleeding episodes, creating bias in the TIPS arm of the study, because of 
increasing rates of variceal bleeding, overall bleeding, and conceivably, death.  The 
addition of prophylactic antibiotic medications may reduce mortality, thus favoring the 
TIPS arm patients by augmenting their immune systems, thereby increasing survival 
rates.  Similarly, patients in the Romero et al. (2006) EVL treatment arm were medicated 
with sucralfate (1 gram four times daily), and followed with endoscopy at one, three, and 
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six month intervals after variceal eradication, and every six months thereafter throughout 
the treatment period.  In contrast, subjects in the pharmacological treatment arm were 
followed with compliance monitoring visits every three months after reaching 
hemodynamic goal endpoints, but the study analysis did not indicate that this group 
received any further endoscopy or sucralfate.  Since endoscopy may result in mucosal 
tears or hemorrhage and esophageal perforation, the subjects in the EVL treatment arm 
may be predisposed to an increased rate of esophageal bleeding, overall bleeding, and 
mortality.  The addition of sucralfate to the ligation group, but not to the pharmacological 
group, could create a reverse bias effect by decreasing esophageal mucosal lining 
irritability and likelihood to bleed.  Studies that include disparate variables and unequal 
treatments, such as those described above, reduce the ability to link cause and effect and 
hence, study validity.   
The duration of studies in the published literature differed markedly, providing 
potential for the data to be misunderstood, and resulting in an incorrect analysis.  Given 
the high rate of patient mortality in the immediate three month to one year follow-up after 
an index bleed, study length has a huge impact when considering data analysis regarding 
long-term treatment efficacy, side effects, complications, morbidity, and mortality.  One 
pharmacological study reviewed had a two week gastroscopy follow up that only 69% of 
the patients submitted to.8  Another study, involving 324 patients, dosed subjects with 
vasoactive medications for only 72 hours, and had established the study duration as the 
hospital stay only, due to a large percentage of study subjects who lived in remote areas 
and were lost to follow up6.  These studies are well executed, and valid in their own right, 
but cannot truly be compared side-by-side with trials that have a longer duration of study.  
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The shortest study length included in this review was 11.8 months.  A number of variceal 
rebleeding studies with a shorter duration were excluded because they did not target long-
term variceal rebleeding prevention. 
Likewise, choices of inclusion and exclusion criteria regarding patient populations 
were significantly variable.  While five of six of the included studies specified only 
cirrhotic patients, Sarin et al (2005) included and compared study results with patients 
suffering from cirrhosis and noncirrhotic portal hypertension.  Sauer et al. (2002) 
included 12 patients with a history of previous variceal bleeding which had occurred at 
least six months prior to the index bleed, but had not received any medical or endoscopic 
treatment.  The remaining 73 patients in this study had a history of only the index 
bleeding episode, which is more consistent with inclusion criteria in the comparative 
studies.  One excluded study included patients as young as 16 years of age, while most 
trials included only patients18 years and up.  As studies quantify and measure death and 
comorbidities, this age difference may produce an age-biased result, both, because the 
subject has not had the disease state for as long a time and, secondly, they may be 
healthier overall, due to their youth.  Some trials measured outcomes in only alcoholic 
cirrhotic patients4, whereas others included any type of cirrhosis, whether it was induced 
by virus, Wilson’s disease, autoimmune etiology, primary biliary cirrhosis, Budd-Chiari 
syndrome, or cryptogenic in nature.   
Of the six studies, two were performed at more than one clinical site.  The de la 
Peña et al. (2005) study was a multicenter trial conducted at four sites, while the Romero 
et al. (2006) study took place at two facilities.  Having consistency at separate sites, 
regarding: (1) controls, (2) definitions of events, or (3) choice of intervention, requires 
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greater oversight and coordination than simply designing the trial around one location.  
Pomier-Layrargues et al. (2001) specifically conducted their study as a single-center trial 
“to avoid bias that may result from the differences in technical expertise in different 
centers and also to control for the accuracy of critical information such as (rates of) 
rebleeding, occurrence of encephalopathy, and cause of death.”5 
As these studies are of a highly varied nature, it creates a quagmire of data.  While 
ultimately likely to be of use in the pursuit of more effective therapy, such data is 
difficult to wade through to extract the necessary information required to make fully 
informed, non-biased decisions regarding the best and most appropriate care available for 
each individual. 
The included randomized controlled trials of esophageal variceal ligation 
compared to other therapies are seen in Table II.  Five of the six trials maintained one 
arm of the study solely using esophageal variceal ligation, helping to compare like 
studies.  (The sixth, Sauer et al20, augmented the use of EVL with twice daily doses of 
propranolol, then compared that combination therapy to TIPS, to assess whether the 
addition of a beta-blocker to ligation could improve EVL outcome in regards to 
prevention of secondary variceal bleeding, since no trials had yet measured this 
combination in a long-term study).  As we can see in Table II, variceal rebleeding rates 
using EVL alone range between 7% and 56.4%, with death rates ranging from 8.5% to 
42%, as compared to rebleeding rates of 9.3% to 36%, and death rates ranging from 
11.6% to 41.5% for comparison studies.  Except for the trial by Sarin et al. (2005) pairing 
EVL against propranolol plus ISMN, none of the other trials showed a benefit in the 
long-term prevention of variceal rebleeding by esophageal variceal ligation alone, as 
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compared to beta-blocker plus nitrate, EVL plus beta-blocker, or TIPS.  The results 
showing TIPS to be more effective than EVL is not a surprise: studies have shown that 
transesophageal intrahepatic portosystemic stent treatment reduces the incidence of 
variceal rebleeding through a reduction in portal pressure, but does so at the risk of a 
greater incidence of encephalopathy, higher treatment costs, and without improvement in 
mortality.11  However, why do the other four studies in this review result in variceal 
rebleeding data that do not seem to support the industry-accepted standard that has made 
EVL the treatment of choice for secondary prophylaxis of variceal rebleeding? 
On closer examination, we see, of the three studies comparing solely variceal 
ligation therapy to pharmacological therapy, the study by Sarin et al (2005) claimed equal 
benefit between EVL and combination drug therapy, Romero et al (2006), likewise, 
reported no superiority of EVL over nadolol plus ISMN for the prevention of variceal 
rebleeding, while, in contrast, Villanueva et al.18 showed a greater benefit with 
pharmacological treatment.  The Sarin et al. (2005) report specified an equal benefit from 
both ligation and combination pharmacological therapy when applied to cirrhotic 
patients, but added that EVL is more effective in secondary variceal rebleeding when 
applied to patients with noncirrhotic portal hypertension.  Villanueva et al.18 reported a 
benefit with combination nadolol plus ISMN in both prevention of variceal rebleeding 
and a decreased complication rate.  One explanation for these differences may be the 
study duration.  The Sarin et al17 study duration follow-up of 11.1 months in the 
pharmacological arm, and 12.4 months in the EVL arm, may lead us to misinterpret 
results.  Band ligation therapy does not reduce portal hypertension, or the hepatic venous 
pressure gradient (HVPG), important to variceal rebleeding rate.  Thus, esophageal 
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ligation results in known disadvantages of short-term effectiveness, accompanied by 
frequent variceal recurrence and rebleeding rates.  It is reasonable, then, to extrapolate 
that a study of shorter duration may not be of sufficient length to capture the actual 
rebleeding or complication rates that may come with treatment, and which would 
increase the rebleeding rate of patients treated ligation therapy, possibly changing study 
outcome.  Additionally, the study by Sarin et al.17, comparing EVL to propranolol plus 
ISMN, had the highest percentage of Child’s class A patients than any of the other studies 
by far (the average percentage of patients in Child classification A for both arms of this 
study is 45.5%, as compared to the overall average of 24.4% Child A subjects in the other 
studies combined).  A disproportionate amount of Child A subjects in a study decreases 
the overall severity of liver disease in that patient population, which, in turn, decreases 
the likelihood of variceal rebleeding and increases the patient’s one- and two-year 
survival rate.  A last consideration is that Sarin et al.17 included both cirrhotic and 
noncirrhotic patients (73.7 and 26.3%, respectively), as opposed to every other study 
reviewed here, which included only cirrhotic populations.  Inclusion of noncirrhotic 
subjects decreases the risk of variceal rebleeding for this selected population because 
liver function is better preserved in noncirrhotic patients, thereby translating to a 
reduction in variceal bleeding rate for the overall study results. 
The randomized control trials by Romero et al.15 and Villanueva et al.18 both 
compared EVL to nadolol plus isosorbide mononitrate (ISMN) and resulted in lower rates 
of variceal rebleeding and death among subjects in the pharmacological arm of the 
studies.  These two studies reported pharmacological variceal rebleeding rates between 
28% and 36%, and death rates from 21.2% to 32%, as opposed to higher rates of variceal 
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rebleeding and death rates with variceal ligation (40% to 44%, and 46% to 49%, 
respectively).  Romero et al.15 did not find any advantage in EVL over pharmacologic 
therapies, and used lower dosages of medications: 88mg+ 68mg of nadolol daily and 
57.7mg + 27mg ISMN.  In comparison, the study by Villanueva et al.18, which used a 
mean dose of 96mg +56mg nadolol per day, augmented by a mean dose of isosorbide 
mononitrate at 66mg+22mg per day, concluded that combination therapy is more 
effective than endoscopic ligation for the prevention of recurrent bleeding and associated 
with lower rates of major complications.  Sarin et al.17 may also have achieved lower 
rebleeding rates and death rates than either of these studies secondary to their use of 
higher dosages of beta-blocker (mean propranolol dose 109mg+46mg per day) and nitrate 
(mean dose of ISMN was 34.2mg+11.7mg per day).  
Another explanation could be the advent of a new therapeutic standard as a result 
of combining previously accepted treatment modalities.  The RCT by de la Peña et al.19 
showed nadolol plus variceal ligation to be significantly more effective at reducing the 
incidence of variceal rebleeding and reducing overall upper GI bleeding, when compared 
to EVL therapy alone, but that it did not significantly change mortality rate.  By 
combining a beta-blocker, to reduce portal blood flow, and ligation, which results in a 
reduction of rebleeding, complications, and deaths, as compared to endoscopic 
sclerotherapy11, and which does not carry the higher attendant risk of encephalopathy that 
TIPS or portocaval shunt surgery do, this pairing may optimize patient outcomes without 
increasing the incidence of variceal rebleeding, overall upper GI hemorrhage rate, 
complications, or contraindications. 
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This benefit of combined therapy seems to be substantiated by the remaining 
study comparing variceal ligation plus propranolol, another nonselective beta-blocker, to 
TIPS therapy.  As we can see in Table II, variceal rebleeding rates using EVL ranged 
between 7% and 56.4%, with death rates ranging from 8.5% to 42%.  The study by Sauer 
et al.20, marrying EVL with propranolol, falls somewhere in the middle, with a variceal 
rebleeding rate of 23.8%, and a death rate of 17.8%.  Upon closer inspection, Sauer’s 
23.8% variceal rebleeding rate is one the lowest EVL-induced variceal rebleeding rates, 
with the exception of the study results by Sarin et al.17 (7%) and by de la Peña et al.19 
(9.3%), both of which are rebleeding rates for EVL combined with nadolol, a different 
beta-blocker.  The important thing to observe is that the rebleeding rate by Sarin et al.17 
of 7% using EVL in isolation, was achieved with the factors listed above, and that the 
variceal rebleeding and death rates by Sauer et al.20 were accomplished with the longest 
follow-up period, 43.2 months, a more balanced Child’s classification patient profile and 
use of a cirrhotic-only study population, adding import to use of ligation plus beta-
blocker, and giving cause for further study of this combination therapy.  Additionally, 
although the TIPS arm of the study by Sauer et al. (2002) did, in fact, have a significantly 
lower variceal rebleeding rate than the EVL plus propranolol arm (16.3% versus 23.8%, 
respectively) it also resulted in an increased mortality rate (24.1% versus 17.8%), which 
does not contradict other studies comparing TIPS and EVL.  One must conclude, 
regarding the increased mortality associated with TIPs therapy, as shown with the study 
by Sauer et al.20, it doesn’t make sense to recommend a TIPS treatment protocol to a 
patient unless it is after safer treatments have been unsuccessful, as is current industry 
protocol. 
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The 2005 study by Pomier-Layrargues et al.5, comparing EVL to TIPS, in a study 
of intermediate duration, showed a significant benefit from TIPS therapy in the reduction 
of variceal rebleeding and in overall upper GI bleeding rates.  Additionally, it did not 
show any difference in mortality rate at two years, and, interestingly, did not show a 
significant difference in the rate of encephalopathy at two years between the two 
treatment modalities.  It is unclear whether this study’s use of only Child’s B class patient 
population was instrumental in this lack of difference.  One problem with comparing this 
study to the others is in the timing of treatments after control of the initial variceal 
bleeding and subsequent randomization.  The study design required that the patient be 
hemodynamically stable for at least 24 hours after the initial bleeding episode was 
controlled, then randomization to separate treatment arms occurred.  Ligation first 
occurred on day one after randomization, while TIPS procedure occurred within 72 
hours.  Since variceal rebleeding can occur as frequently as 30% to 50% within the first 
day of the acute episode11 this difference in starting times for treatment arms may have 
had an effect on rebleeding rates and mortality rates. 
 
RECOMMENDATIONS FOR FURTHER STUDY 
As much as possible, studies on long term variceal bleeding prevention therapies 
will need to be performed in a uniform manner to equally facilitate therapy effectiveness 
and to equally measure the likelihood of side effect profiles and mortality. 
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LIMITATIONS OF STUDY 
While the six studies provide a solid foundation for the evaluation of esophageal 
variceal ligation therapy, the inclusion of additional studies would help further assess 
whether EVL is the preferred treatment for the prophylaxis of variceal rebleeding.  
Several recent studies were unavailable for review, but based upon the abstracts, these 
studies would provide a valuable contribution to this evaluation. Additionally, all studies 
performed prior to 1999 were excluded because of technological and pharmacological 
advances; other studies were omitted because they were not available in the English 
language.  However, due to these somewhat arbitrary constraints, valid trials may have 
been omitted. 
 
CONCLUSION 
Esophageal variceal ligation, alone, shows no superiority to treatment with beta-
blocker and nitrate, or TIPS procedure, and is less effective than EVL plus nadolol in the 
prevention of variceal rebleeding.  While the ideal option for primary or subsequent 
esophageal variceal bleeding would be safe and effective prophyllactic prevention, 
current treatments remain moderately efficacious and there remains the need for 
effective, safe, preventive therapeutic modalities after immediate emergency rescue 
treatment.  Therapies such as endoscopic injection sclerotherapy (EIS) and TIPS are not 
effective as prophyllaxis, as the EIS-associated risk of bleeding and esophageal stricture, 
and increased rates of TIPS-associated hepatic encephalopathy and increased mortality 
are not logical if we keep in mind the patient’s quality of life and reason for treatment.  
Therefore, because additional trials and advances in pharmacology are improving 
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treatment of increased portal hypertension, and technological improvements are occuring 
constantly, the combination therapy effect seems to be a reasonable direction for future 
study.  These current trials do not support esophageal variceal ligation alone as the most 
efficacious treatment available, but rather indicate that ligation may be improved when 
used with a beta-blocker.  An approach which promotes secondary prophylaxis of 
variceal rebleeding through pharmacological therapy and concurrent endoscopic ligation, 
seems promising and necessary. The evidence remains controversial regarding the 
effectiveness of variceal ligation therapy when used in isolation; however, there is strong 
evidence of therapeutic improvement when ligation is augmented by beta-blocker 
therapy. 
Table I: Literature Review 
Key: EVL: esophageal variceal ligation; ISMN: isosorbide mononitrate or 5-isosorbide mononitrate; NCPH: noncirrhotic portal 
hypertension; TIPS: transesophageal intrahepatic portosystemic stent       35 
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endoscopy.  
Endoscopic 
variceal 
ligation 
every 2 
weeks until 
variceal 
obliteration 
versus 
propranolol 
plus ISMN  
Bleeding 
versus no 
bleed 
 
EVL arm 14.1% 
rebleed rate 
versus 27.2% 
drug therapy 
arm rebleed 
rate.  EVL more 
effective than 
drug therapy in 
patients with 
noncirrhotic 
portal 
hypertention 
(NCPH), but 
equally effective 
in cirrhotic 
patients. 
 RCT J = 3  Mean follow 
up 11.8mos.  
         
13/de la Pena et 
al/ Variceal 
ligation plus 
2005 80 cirrhotic 
adults, aged 
18-75, with 
Esophageal 
variceal 
ligation 
Primary 
endpoints 
variceal 
Rebleeding rate 
EVL + nadolol 
=14% (6/43 
RCT, not 
blinded 
J=3 Mean f/up 
15 +/_ 8mos 
in EVL 
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Author/title/ 
Journal 
Year 
Pub-
lished 
Patients/ 
Population 
Intervention Comparison Outcome(s) Study Type Validity 
(Jadad 
Score) 
 
Comments 
nadolol 
compared with 
ligation for 
prophylaxis of 
variceal 
rebleeding: a 
multi center 
trial19/Hepatolog
y 
esophageal 
varices or 
esophago-
gastric type 
gastroesoph
ageal 
varices. 
(EVL) 
alone, 
versus EVL 
with daily 
oral nadolol  
rebleeding or 
not. Several 
secondary 
endpoints. 
pts), for EVL 
alone 38% 
(14/37 pts) 
group, 
17.5+/- 7.8 
months in 
EVL+ 
nadolol 
group.  
Study 
performed at 
four sites. 
         
14/Romero et al/ 
Comparative 
study between 
nadolol and 5-
isosorbide 
mononitrate vs. 
endoscopic band 
ligation plus 
sclerotherapy in 
the prevention 
of variceal 
rebleeding in 
cirrhotic 
patients: a 
randomized 
controlled 
2006 109 
cirrhotic 
patients 
with a 
recent 
variceal 
bleed 
Once daily 
oral nadolol 
titrated 
upwards 
until 25% 
reduction 
HR or until 
55 bpm. 
Then daily 
BID 5-
ISMN 
added. In 
EVL group, 
banding @ 
2wks until 
eradication. 
GI and 
variceal 
rebleeding or 
not were the 
primary 
endpoints. 
No differences 
in variceal 
rebleeding (40% 
versus 36%) in 
nadolol+5-
ISMN and EVL 
groups, 
respectively. 
RCT J=3 Mean follow 
up 17 and 19 
months in 
nadolol+5-
ISMN and 
EVL groups, 
res-
pectively.  
Study per-
formed at 
two sites. 
Table I: Literature Review 
Key: EVL: esophageal variceal ligation; ISMN: isosorbide mononitrate or 5-isosorbide mononitrate; NCPH: noncirrhotic portal 
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Author/title/ 
Journal 
Year 
Pub-
lished 
Patients/ 
Population 
Intervention Comparison Outcome(s) Study Type Validity 
(Jadad 
Score) 
 
Comments 
trial15/ 
Alimentary 
Pharmacology 
& Therapeutics 
 
         
7/ Pomier-
Layragues, G, et 
al/Transjugular 
intrahepatic 
portosystemic 
shunt (TIPS) 
versus 
endoscopic 
variceal ligation 
in the prevention 
of variceal 
rebleeding in 
patients with 
cirrhosis: a 
randomized 
trial5/ Gut 
2001 80 patients, 
aged 18-75 
years, with 
cirrhosis 
and an 
episode of 
variceal 
hemorrhage
. 
Intrahepatic 
portosystem
ic stent(s) 
placed 
versus EVL. 
Rebleeding 
incidence at 2 
yrs was a 
secondary 
endpoint.  
Variceal 
rebleeding rate 
at two years 
18.5% with 
TIPS vs 66% 
with EVL. 
RCT J=3 Mean follow 
up 628 days 
(20.9mos).  
         
8/Villanueva, C, 
et al/ endoscopic 
ligation 
compared with 
2001 144 adults, 
aged 18 and 
up, with 
cirrhosis 
EVL versus 
daily oral 
nadolol plus 
BID 
Recurrent 
bleeding or 
no bleeding. 
49% rebleed 
rate for EVL, 
33% for 
medication 
RCT J=3 Median 
follow-up 21 
months. 
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Author/title/ 
Journal 
Year 
Pub-
lished 
Patients/ 
Population 
Intervention Comparison Outcome(s) Study Type Validity 
(Jadad 
Score) 
 
Comments 
combined 
treatment with 
nadolol and 
isosorbide 
mononitrate to 
prevent 
recurrent 
variceal 
bleeding18/ The 
New England 
Journal of 
Medicine 
and 
esophageal 
variceal 
hemorrhage
. 
isosorbide 
mononitrate  
treatment. 
10/Sauer, P, et 
al/ Endoscopic 
variceal ligation 
plus propranolol 
vs. transjugular 
intrahepatic 
portosystemic 
stent shunt: a 
long-term 
randomized 
trial20/Endoscop
y 
2002 85 cirrhotic 
adults, aged 
31-87, with 
single 
episode of 
acute 
esophageal 
variceal 
bleed. 
EVL plus 
propranolol 
versus TIPS 
Control of 
bleed. 
EVL group 
23.8% rebleed 
rate vs 16.3% 
rebleed rate for 
TIPS group. 
RCT J=3 Mean study 
length 4.1 
yrs in TIPS 
group, 3.6 
yrs in EVL 
group. 
  
Table II: Trials Comparing Esophageal Variceal Ligation versus Other Therapies 
 
Key: EVL: esophageal variceal ligation. ISMN: isosorbide mononitrate. TIPS: transesophageal intrahepatic portosystemic 
shunt 
                39 
Author (year) Treatments 
compared 
n Child 
A 
Child 
B 
Child 
C 
Follow- 
Up 
(mo) 
% Variceal 
Rebleeding 
% Overall 
Rebleeding 
Death 
Rate % 
Sarin 
(2005) 17 EVL 71 50 36 14 12.4 7 14.1 8.5 
 Propranolol 
+ ISMN 
66 41 42 17 11.1 22.7 27.2 6.1 
Romero 
(2006) 15 EVL 52 32 58 10 19 40 46 19.2 
 Nadolol + 
ISMN 
57 40 44 16 17 36 47 21.2 
Villanueva 
(2001) 18 EVL 72 15 60 25 22 44 49 42 
 Nadolol + 
ISMN 
72 26 54 19 20 28 33 32 
De la Peña 
(2005) 19 EVL 37 16 54 30 15 27 38 10.8 
 EVL + 
Nadolol 
43 14 58 28 17.5 9.3 14 11.6 
Pomier- 
Layrargues 
  (2005) 5 EVL 39 0 100 0 19.4 56.4 79 41.0 
 TIPS 41 0 100 0 22.6 19.5 34 41.5 
Sauer 
(2002) 20 EVL + Propranolol 42 24 45 31 43.2 23.8 NR 17.8 
 TIPS 43 35 37 28 49.2 16.3 NR 24.1 
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